Younger age at initiation of the human papillomavirus (HPV) vaccination series is associated with higher rates of on-time completion

被引:55
作者
St Sauver, Jennifer L. [1 ,2 ]
Rutten, Lila J. Finney [1 ,2 ]
Ebbert, Jon O. [2 ,4 ]
Jacobson, Debra J. [2 ,5 ]
McGree, Michaela E. [2 ,5 ]
Jacobson, Robert M. [2 ,3 ]
机构
[1] Mayo Clin, Div Epidemiol, Dept Hlth Sci Res, 200 First St, Rochester, MN 55905 USA
[2] Mayo Clin, Coll Med, Robert D & Patricia E Kern Ctr Sci Hlth Care Deli, 200 First St, Rochester, MN 55905 USA
[3] Mayo Clin, Div Community Pediat & Adolescent Med, Dept Pediat & Adolescent Med, 200 First St, Rochester, MN 55905 USA
[4] Mayo Clin, Div Primary Care Internal Med, Dept Med, 200 First St, Rochester, MN 55905 USA
[5] Mayo Clin, Div Biomed Stat & Informat, Dept Hlth Sci Res, 200 First St, Rochester, MN 55905 USA
基金
美国国家卫生研究院;
关键词
Papillomavirus vaccines; vaccination; Immunization programs; Immunization; Patient acceptance of health care; Patient compliance; UNITED-STATES; ADVISORY-COMMITTEE; PARTICLE VACCINE; LONG-TERM; IMMUNOGENICITY; ADOLESCENTS; TYPE-11; RECOMMENDATIONS; INFECTION; EFFICACY;
D O I
10.1016/j.ypmed.2016.02.039
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Vaccination rates for human papillomavirus (HPV) have remained disappointingly low. It is critical to identify methods to increase on-time vaccine series completion rates (before 13 or 15 years). To determine whether younger age (9 to 10 years of age) at HPV vaccine series initiation was associated with improved on-time completion rates compared to initiation at 11 to 12 years, we examined the prevalence of on-time HPV vaccine series completion rates from August 2006 through December 2012 in a large, population-based cohort of children and adolescents (aged 9.5 to 27 years) residing in Olmsted County, MN on December 31, 2012 (n = 36,223). We compared age at vaccine initiation between individuals who successfully completed both 2 and 3 doses of the vaccination series on-time (before age 13.5 or 15.0 years) using multivariate logistic regression. On-time completion of both 2 and 3 doses of the vaccine series by age 13.5 or 15.0 years was significantly associated with initiation at 9 to 10 years as compared to 11 to 12 years after adjusting for sex, race, insurance status, frequent health care visits, and year of first vaccination (all p < .01). Interventions focused on beginning the vaccination series at 9 to 10 years of age may result in higher rates of timely series completion. (C) 2016 Elsevier Inc. All rights reserved.
引用
收藏
页码:327 / 333
页数:7
相关论文
共 32 条
  • [1] Anonymous, 2010, Morbidity and Mortality Weekly Report, V59, P630
  • [2] Anonymous, 2010, Morbidity and Mortality Weekly Report, V59, P626
  • [3] Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women
    Block, Stan L.
    Nolan, Terry
    Sattler, Carlos
    Barr, Eliav
    Giacoletti, Katherine E. D.
    Marchant, Colin D.
    Castellsague, Xavier
    Rusche, Steven A.
    Lukac, Suzanne
    Bryan, Janine T.
    Cavanaugh, Paul F., Jr.
    Reisinger, Keith S.
    [J]. PEDIATRICS, 2006, 118 (05) : 2135 - 2145
  • [4] Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States
    Chaturvedi, Anil K.
    Engels, Eric A.
    Pfeiffer, Ruth M.
    Hernandez, Brenda Y.
    Xiao, Weihong
    Kim, Esther
    Jiang, Bo
    Goodman, Marc T.
    Sibug-Saber, Maria
    Cozen, Wendy
    Liu, Lihua
    Lynch, Charles F.
    Wentzensen, Nicolas
    Jordan, Richard C.
    Altekruse, Sean
    Anderson, William F.
    Rosenberg, Philip S.
    Gillison, Maura L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (32) : 4294 - 4301
  • [5] Curtis CR, 2013, MMWR-MORBID MORTAL W, V62, P685
  • [6] D'Addario M, 2014, EVIDENCE BASED RECOM
  • [7] Human Papillomavirus Vaccination of Females in a Large Health Claims Database in the United States, 2006-2012
    Dunne, Eileen F.
    Stokley, Shannon
    Chen, Weiwei
    Zhou, Fangjun
    [J]. JOURNAL OF ADOLESCENT HEALTH, 2015, 56 (04) : 408 - 413
  • [8] Long-term Study of a Quadrivalent Human Papillomavirus Vaccine
    Ferris, Daron
    Samakoses, Rudiwilai
    Block, Stan L.
    Lazcano-Ponce, Eduardo
    Alberto Restrepo, Jaime
    Reisinger, Keith S.
    Mehlsen, Jesper
    Chatterjee, Archana
    Iversen, Ole-Erik
    Sings, Heather L.
    Shou, Qiong
    Sausser, Timothy A.
    Saah, Alfred
    [J]. PEDIATRICS, 2014, 134 (03) : E657 - E665
  • [9] Fiore Anthony E., 2007, Morbidity and Mortality Weekly Report, V56, P1
  • [10] Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine
    Giuliano, Anna R.
    Lazcano-Ponce, Eduardo
    Villa, Luisa
    Nolan, Terry
    Marchant, Colin
    Radley, David
    Golm, Greg
    McCarroll, Kathleen
    Yu, Jimmy
    Esser, Mark T.
    Vuocolo, Scott C.
    Barr, Eliav
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2007, 196 (08) : 1153 - 1162